Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma

This study has suspended participant recruitment.
(Revisions due - Enroll to cohort 2)
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Stanton Gerson MD, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01269424
First received: December 31, 2010
Last updated: December 20, 2016
Last verified: December 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: June 2018
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)